Double-Punch drug trial aims to knock out stubborn blood cancer
NCT ID NCT06453044
Summary
This study is testing a combination of two targeted drugs, mosunetuzumab and polatuzumab vedotin, for people with follicular lymphoma that has come back or not responded to previous treatments. The goal is to see if using these two drugs together is safe and can eliminate detectable cancer (complete response) in more patients. It is enrolling 41 adults who have had at least one prior therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GRADE 1 FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope Orange County Lennar Foundation Cancer Center
NOT_YET_RECRUITINGIrvine, California, 92618, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.